TIO Bioventures
  • About
  • Portfolio
  • News
  • Connect
Select Page

Treadwell Announces Initiation New Clinical Trial CFI 400945

by treadwell | Oct 19, 2020 | Uncategorized

Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer...

TIO-Bioventures-Launches-TCRyption-TCR-T-cell-based

by treadwell | Oct 8, 2020 | Uncategorized

TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based Immunotherapy...

Recent Posts

  • Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
  • Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945
  • Treadwell Announces Initiation New Clinical Trial CFI 400945
  • TIO-Bioventures-Launches-TCRyption-TCR-T-cell-based
  • Treadwell-Announces-Initiation-Patient-Dosing-TWT-101-Phase

Recent Comments

    Archives

    • April 2021
    • December 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Whos theme My Theme | Powered by MyPress | Designed by Your Design Agency